glp 1 agonist mechanism of action GLP-1 and Anesthesia: Considerations and Cautions for CRNAs Mechanisms of Action and Therapeutic
Description
Sources Consulted Secondary data for the market study was gathered from multiple credible sources, including: Government databases, regulatory bodies, and public institutions International organizations (WHO, OECD, IMF, World Bank, etc.) Commercial and paid databases Industry associations, trade publications, and technical journals Company annual reports, investor presentations, press releases, and SEC filings Academic research papers, patents, and scientific literature Previous market research publications and syndicated reports These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights
References Wharton S, Blevins T, Chen L, et al
Diabetes Obes Metab 15(1):1527 Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Hao T, Zhang H, Li S, Tian H
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Compliance with Ethics Guidelines This article is based on previously conducted studies and is not a new study with human participants or animals
